Ethanol inhibits dopamine uptake via organic cation transporter 3: Implications for ethanol and cocaine co-abuse.
Journal
Molecular psychiatry
ISSN: 1476-5578
Titre abrégé: Mol Psychiatry
Pays: England
ID NLM: 9607835
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
05
10
2022
accepted:
29
03
2023
revised:
20
12
2022
medline:
1
11
2023
pubmed:
13
6
2023
entrez:
12
6
2023
Statut:
ppublish
Résumé
Concurrent cocaine and alcohol use is among the most frequent drug combination, and among the most dangerous in terms of deleterious outcomes. Cocaine increases extracellular monoamines by blocking dopamine (DA), norepinephrine (NE) and serotonin (5-HT) transporters (DAT, NET and SERT, respectively). Likewise, ethanol also increases extracellular monoamines, however evidence suggests that ethanol does so independently of DAT, NET and SERT. Organic cation transporter 3 (OCT3) is an emergent key player in the regulation of monoamine signaling. Using a battery of in vitro, in vivo electrochemical, and behavioral approaches, as well as wild-type and constitutive OCT3 knockout mice, we show that ethanol's actions to inhibit monoamine uptake are dependent on OCT3. These findings provide a novel mechanistic basis whereby ethanol enhances the neurochemical and behavioral effects of cocaine and encourage further research into OCT3 as a target for therapeutic intervention in the treatment of ethanol and ethanol/cocaine use disorders.
Identifiants
pubmed: 37308680
doi: 10.1038/s41380-023-02064-5
pii: 10.1038/s41380-023-02064-5
pmc: PMC10615754
doi:
Substances chimiques
Dopamine
VTD58H1Z2X
Ethanol
3K9958V90M
Carrier Proteins
0
Cocaine
I5Y540LHVR
Serotonin
333DO1RDJY
Cations
0
Dopamine Plasma Membrane Transport Proteins
0
Serotonin Plasma Membrane Transport Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2934-2945Subventions
Organisme : NIMH NIH HHS
ID : R01 MH093320
Pays : United States
Organisme : NIDA NIH HHS
ID : R21 DA046044
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA031115
Pays : United States
Organisme : NIDA NIH HHS
ID : U18 DA052527
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH093320
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Grant BF, Chou SP, Saha TD, Pickering RP, Kerridge BT, Ruan WJ, et al. Prevalence of 12-month alcohol use, high-risk drinking, and dsm-iv alcohol use disorder in the united states, 2001-2002 to 2012-2013: Results from the national epidemiologic survey on alcohol and related conditions. JAMA Psychiatry. 2017;74:911–23.
pubmed: 28793133
pmcid: 5710229
doi: 10.1001/jamapsychiatry.2017.2161
Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, et al. Epidemiology of dsm-5 alcohol use disorder: Results from the national epidemiologic survey on alcohol and related conditions iii. JAMA Psychiatry. 2015;72:757–66.
pubmed: 26039070
pmcid: 5240584
doi: 10.1001/jamapsychiatry.2015.0584
Staines GL, Magura S, Foote J, Deluca A, Kosanke N. Polysubstance use among alcoholics. J Addict Dis. 2001;20:53–69.
pubmed: 11760926
doi: 10.1300/J069v20n04_06
Jones AW, Kugelberg FC, Holmgren A, Ahlner J. Drug poisoning deaths in sweden show a predominance of ethanol in mono-intoxications, adverse drug-alcohol interactions and poly-drug use. Forensic Sci Int. 2011;206:43–51.
pubmed: 20630671
doi: 10.1016/j.forsciint.2010.06.015
Koski A, Ojanpera I, Vuori E. Interaction of alcohol and drugs in fatal poisonings. Hum Exp Toxicol. 2003;22:281–7.
pubmed: 12774892
doi: 10.1191/0960327103ht324oa
van Amsterdam J, Brunt TM, Pierce M, van den Brink W. Hard boiled: Alcohol use as a risk factor for MDMA-induced hyperthermia: A systematic review. Neurotox Res. 2021;39:2120–33.
pubmed: 34554408
pmcid: 8639540
doi: 10.1007/s12640-021-00416-z
Thai D, Dyer JE, Benowitz NL, Haller CA. Gamma-hydroxybutyrate and ethanol effects and interactions in humans. J Clin Psychopharmacol. 2006;26:524–9.
pubmed: 16974199
pmcid: 2766839
doi: 10.1097/01.jcp.0000237944.57893.28
Liechti ME, Kunz I, Greminger P, Speich R, Kupferschmidt H. Clinical features of gamma-hydroxybutyrate and gamma-butyrolactone toxicity and concomitant drug and alcohol use. Drug Alcohol Depend. 2006;81:323–6.
pubmed: 16143455
doi: 10.1016/j.drugalcdep.2005.07.010
Connor JP, Gullo MJ, White A, Kelly AB. Polysubstance use: Diagnostic challenges, patterns of use and health. Curr Opin Psychiatry. 2014;27:269–75.
pubmed: 24852056
doi: 10.1097/YCO.0000000000000069
Barrett SP, Gross SR, Garand I, Pihl RO. Patterns of simultaneous polysubstance use in Canadian rave attendees. Subst Use Misuse. 2005;40:1525–37.
pubmed: 16048831
doi: 10.1081/JA-200066866
Grant BF, Harford TC. Concurrent and simultaneous use of alcohol with cocaine: Results of national survey. Drug Alcohol Depend. 1990;25:97–104.
pubmed: 2323315
doi: 10.1016/0376-8716(90)90147-7
Caetano R, Weisner C. The association between dsm-iii-r alcohol dependence, psychological distress and drug use. Addiction. 1995;90:351–9.
pubmed: 7735020
doi: 10.1111/j.1360-0443.1995.tb03783.x
Martin CS, Clifford PR, Maisto SA, Earleywine M, Kirisci L, Longabaugh R. Polydrug use in an inpatient treatment sample of problem drinkers. Alcohol Clin Exp Res. 1996;20:413–7.
pubmed: 8727229
doi: 10.1111/j.1530-0277.1996.tb01067.x
Liu Y, Williamson V, Setlow B, Cottler LB, Knackstedt LA. The importance of considering polysubstance use: Lessons from cocaine research. Drug Alcohol Depend. 2018;192:16–28.
pubmed: 30195242
pmcid: 7450360
doi: 10.1016/j.drugalcdep.2018.07.025
Vanek VW, Dickey-White HI, Signs SA, Schechter MD, Buss T, Kulics AT. Concurrent use of cocaine and alcohol by patients treated in the emergency department. Ann Emerg Med. 1996;28:508–14.
pubmed: 8909272
doi: 10.1016/S0196-0644(96)70114-2
McCance-Katz EF, Kosten TR, Jatlow P. Concurrent use of cocaine and alcohol is more potent and potentially more toxic than use of either alone—a multiple-dose study. Biol Psychiatry. 1998;44:250–9.
pubmed: 9715356
doi: 10.1016/S0006-3223(97)00426-5
Farre M, de la Torre R, Llorente M, Lamas X, Ugena B, Segura J, et al. Alcohol and cocaine interactions in humans. J Pharm Exp Ther. 1993;266:1364–73.
Higgins ST, Roll JM, Bickel WK. Alcohol pretreatment increases preference for cocaine over monetary reinforcement. Psychopharmacology. 1996;123:1–8.
pubmed: 8741948
doi: 10.1007/BF02246274
Hedaya MA, Pan WJ. Effect of alcohol coadministration on the plasma and brain concentrations of cocaine in rats. Drug Metab Dispos. 1997;25:647–50.
pubmed: 9152606
Lindholm S, Rosin A, Dahlin I, Georgieva J, Franck J. Ethanol administration potentiates cocaine-induced dopamine levels in the rat nucleus accumbens. Brain Res. 2001;915:176–84.
pubmed: 11595207
doi: 10.1016/S0006-8993(01)02847-5
Russo SJ, Nestler EJ. The brain reward circuitry in mood disorders. Nat Rev Neurosci. 2013;14:609–25.
pubmed: 23942470
doi: 10.1038/nrn3381
Pennings EJ, Leccese AP, Wolff FA. Effects of concurrent use of alcohol and cocaine. Addiction. 2002;97:773–83.
pubmed: 12133112
doi: 10.1046/j.1360-0443.2002.00158.x
Tallarida CS, Bires K, Avershal J, Tallarida RJ, Seo S, Rawls SM. Ethanol and cocaine: Environmental place conditioning, stereotypy, and synergism in planarians. Alcohol. 2014;48:579–86.
pubmed: 25212751
pmcid: 4435956
doi: 10.1016/j.alcohol.2014.07.006
Busse GD, Riley AL. Cocaine, but not alcohol, reinstates cocaine-induced place preferences. Pharm Biochem Behav. 2004;78:827–33.
doi: 10.1016/j.pbb.2004.05.020
Ding ZM, Oster SM, Hauser SR, Toalston JE, Bell RL, McBride WJ, et al. Synergistic self-administration of ethanol and cocaine directly into the posterior ventral tegmental area: Involvement of serotonin-3 receptors. J Pharm Exp Ther. 2012;340:202–9.
doi: 10.1124/jpet.111.187245
Aspen JM, Winger G. Ethanol effects on self-administration of alfentanil, cocaine, and nomifensine in rhesus monkeys. Psychopharmacology. 1997;130:222–7.
pubmed: 9151355
doi: 10.1007/s002130050232
John WS, Nader MA. Effects of ethanol on cocaine self-administration in monkeys responding under a second-order schedule of reinforcement. Drug Alcohol Depend. 2017;170:112–9.
pubmed: 27886524
doi: 10.1016/j.drugalcdep.2016.11.002
Pereira RB, Andrade PB, Valentao P. A comprehensive view of the neurotoxicity mechanisms of cocaine and ethanol. Neurotox Res. 2015;28:253–67.
pubmed: 26105693
doi: 10.1007/s12640-015-9536-x
Torres GE, Gainetdinov RR, Caron MG. Plasma membrane monoamine transporters: Structure, regulation and function. Nat Rev Neurosci. 2003;4:13–25.
pubmed: 12511858
doi: 10.1038/nrn1008
Ron D, Barak S. Molecular mechanisms underlying alcohol-drinking behaviours. Nat Rev Neurosci. 2016;17:576–91.
pubmed: 27444358
pmcid: 5131788
doi: 10.1038/nrn.2016.85
Brand I, Fliegel S, Spanagel R, Noori HR. Global ethanol-induced enhancements of monoaminergic neurotransmission: A meta-analysis study. Alcohol Clin Exp Res. 2013;37:2048–57.
pubmed: 23808660
doi: 10.1111/acer.12207
Robinson DL, Volz TJ, Schenk JO, Wightman RM. Acute ethanol decreases dopamine transporter velocity in rat striatum: In vivo and in vitro electrochemical measurements. Alcohol Clin Exp Res. 2005;29:746–55.
pubmed: 15897718
doi: 10.1097/01.ALC.0000164362.21484.14
Mathews TA, John CE, Lapa GB, Budygin EA, Jones SR. No role of the dopamine transporter in acute ethanol effects on striatal dopamine dynamics. Synapse. 2006;60:288–94.
pubmed: 16786536
doi: 10.1002/syn.20301
Lin AM, Bickford PC, Palmer MR, Cline EJ, Gerhardt GA. Effects of ethanol and nomifensine on NE clearance in the cerebellum of young and aged Fischer 344 rats. Brain Res. 1997;756:287–92.
pubmed: 9187345
doi: 10.1016/S0006-8993(97)00229-1
Lin AM, Bickford PC, Palmer MR, Gerhardt GA. Ethanol inhibits the uptake of exogenous norepinephrine from the extracellular space of the rat cerebellum. Neurosci Lett. 1993;164:71–75.
pubmed: 8152619
doi: 10.1016/0304-3940(93)90860-N
Daws LC, Montanez S, Munn JL, Owens WA, Baganz NL, Boyce-Rustay JM, et al. Ethanol inhibits clearance of brain serotonin by a serotonin transporter-independent mechanism. J Neurosci. 2006;26:6431–8.
pubmed: 16775130
pmcid: 6674049
doi: 10.1523/JNEUROSCI.4050-05.2006
Daws LC. Unfaithful neurotransmitter transporters: Focus on serotonin uptake and implications for antidepressant efficacy. Pharm Ther. 2009;121:89–99.
doi: 10.1016/j.pharmthera.2008.10.004
Koepsell H. General overview of organic cation transporters in brain. Handb Exp Pharm. 2021;266:1–39.
doi: 10.1007/164_2021_449
Amphoux A, Vialou V, Drescher E, Bruss M, Mannoury La Cour C, Rochat C, et al. Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006;50:941–52.
pubmed: 16581093
doi: 10.1016/j.neuropharm.2006.01.005
Cui M, Aras R, Christian WV, Rappold PM, Hatwar M, Panza J, et al. The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proc Natl Acad Sci USA. 2009;106:8043–8.
pubmed: 19416912
pmcid: 2683105
doi: 10.1073/pnas.0900358106
Vialou V, Balasse L, Callebert J, Launay JM, Giros B, Gautron S. Altered aminergic neurotransmission in the brain of organic cation transporter 3-deficient mice. J Neurochem. 2008;106:1471–82.
pubmed: 18513366
doi: 10.1111/j.1471-4159.2008.05506.x
Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, et al. Identity of the organic cation transporter oct3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem. 1998;273:32776–86.
pubmed: 9830022
doi: 10.1074/jbc.273.49.32776
Schomig E, Lazar A, Grundemann D. Extraneuronal monoamine transporter and organic cation transporters 1 and 2: A review of transport efficiency. Handb Exp Pharm. 2006;175:151–80.
doi: 10.1007/3-540-29784-7_8
Mayer FP, Schmid D, Owens WA, Gould GG, Apuschkin M, Kudlacek O, et al. An unsuspected role for organic cation transporter 3 in the actions of amphetamine. Neuropsychopharmacology. 2018;43:2408–17.
pubmed: 29773909
pmcid: 6180071
doi: 10.1038/s41386-018-0053-5
Baganz N, Horton R, Martin K, Holmes A, Daws LC. Repeated swim impairs serotonin clearance via a corticosterone-sensitive mechanism: Organic cation transporter 3, the smoking gun. J Neurosci. 2010;30:15185–95.
pubmed: 21068324
pmcid: 3064500
doi: 10.1523/JNEUROSCI.2740-10.2010
Feng N, Telefont M, Kelly KJ, Orchinik M, Forster GL, Renner KJ, et al. Local perfusion of corticosterone in the rat medial hypothalamus potentiates d-fenfluramine-induced elevations of extracellular 5-ht concentrations. Horm Behav. 2009;56:149–57.
pubmed: 19371745
doi: 10.1016/j.yhbeh.2009.03.023
Gasser PJ, Orchinik M, Raju I, Lowry CA. Distribution of organic cation transporter 3, a corticosterone-sensitive monoamine transporter, in the rat brain. J Comp Neurol. 2009;512:529–55.
pubmed: 19025979
doi: 10.1002/cne.21921
Gasser PJ, Lowry CA, Orchinik M. Corticosterone-sensitive monoamine transport in the rat dorsomedial hypothalamus: Potential role for organic cation transporter 3 in stress-induced modulation of monoaminergic neurotransmission. J Neurosci. 2006;26:8758–66.
pubmed: 16928864
pmcid: 6674371
doi: 10.1523/JNEUROSCI.0570-06.2006
Graf EN, Wheeler RA, Baker DA, Ebben AL, Hill JE, McReynolds JR, et al. Corticosterone acts in the nucleus accumbens to enhance dopamine signaling and potentiate reinstatement of cocaine seeking. J Neurosci. 2013;33:11800–10.
pubmed: 23864669
pmcid: 3713722
doi: 10.1523/JNEUROSCI.1969-13.2013
Horton RE, Apple DM, Owens WA, Baganz NL, Cano S, Mitchell NC, et al. Decynium-22 enhances SSRI-induced antidepressant-like effects in mice: Uncovering novel targets to treat depression. J Neurosci. 2013;33:10534–43.
pubmed: 23785165
pmcid: 3685842
doi: 10.1523/JNEUROSCI.5687-11.2013
Kitaichi K, Fukuda M, Nakayama H, Aoyama N, Ito Y, Fujimoto Y, et al. Behavioral changes following antisense oligonucleotide-induced reduction of organic cation transporter-3 in mice. Neurosci Lett. 2005;382:195–200.
pubmed: 15911148
doi: 10.1016/j.neulet.2005.03.014
McReynolds JR, Taylor A, Vranjkovic O, Ambrosius T, Derricks O, Nino B, et al. Corticosterone potentiation of cocaine-induced reinstatement of conditioned place preference in mice is mediated by blockade of the organic cation transporter 3. Neuropsychopharmacology. 2017;42:757–65.
pubmed: 27604564
doi: 10.1038/npp.2016.187
Solanki RR, Scholl JL, Watt MJ, Renner KJ, Forster GL. Amphetamine withdrawal differentially increases the expression of organic cation transporter 3 and serotonin transporter in limbic brain regions. J Exp Neurosci. 2016;10:93–100.
pubmed: 27478387
pmcid: 4957605
doi: 10.4137/JEN.S40231
Baganz NL, Horton RE, Calderon AS, Owens WA, Munn JL, Watts LT, et al. Organic cation transporter 3: Keeping the brake on extracellular serotonin in serotonin-transporter-deficient mice. Proc Natl Acad Sci USA. 2008;105:18976–81.
pubmed: 19033200
pmcid: 2596260
doi: 10.1073/pnas.0800466105
Schmitt A, Mossner R, Gossmann A, Fischer IG, Gorboulev V, Murphy DL, et al. Organic cation transporter capable of transporting serotonin is up-regulated in serotonin transporter-deficient mice. J Neurosci Res. 2003;71:701–9.
pubmed: 12584728
doi: 10.1002/jnr.10521
Monteiro R, Calhau C, Martel F, Guedes de Pinho P, Azevedo I. Intestinal uptake of mpp+ is differently affected by red and white wine. Life Sci. 2005;76:2483–96.
pubmed: 15763079
doi: 10.1016/j.lfs.2004.12.008
Volkow ND, Morales M. The brain on drugs: From reward to addiction. Cell. 2015;162:712–25.
pubmed: 26276628
doi: 10.1016/j.cell.2015.07.046
Fraser-Spears R, Krause-Heuer AM, Basiouny M, Mayer FP, Manishimwe R, Wyatt NA, et al. Comparative analysis of novel decynium-22 analogs to inhibit transport by the low-affinity, high-capacity monoamine transporters, organic cation transporters 2 and 3, and plasma membrane monoamine transporter. Eur J Pharm. 2019;842:351–64.
doi: 10.1016/j.ejphar.2018.10.028
Mitchell NC, Gould GG, Koek W, Daws LC. Ontogeny of SERT expression and antidepressant-like response to escitalopram in wild-type and SERT mutant mice. J Pharm Exp Ther. 2016;358:271–81.
doi: 10.1124/jpet.116.233338
Mitchell NC, Gould GG, Smolik CM, Koek W, Daws LC. Antidepressant-like drug effects in juvenile and adolescent mice in the tail suspension test: Relationship with hippocampal serotonin and norepinephrine transporter expression and function. Front Pharm. 2013;4:131.
doi: 10.3389/fphar.2013.00131
Janowsky A, Neve K, Eshleman AJ Uptake and release of neurotransmitters. Curr Protoc Neurosci. 2001;2:7.9.1–7.9.22.
Mayer FP, Luf A, Nagy C, Holy M, Schmid R, Freissmuth M, et al. Application of a combined approach to identify new psychoactive street drugs and decipher their mechanisms at monoamine transporters. Curr Top Behav Neurosci. 2017;32:333–50.
pubmed: 28025810
doi: 10.1007/7854_2016_63
Mayer FP, Schmid D, Holy M, Daws LC, Sitte HH. “Polytox” synthetic cathinone abuse: A potential role for organic cation transporter 3 in combined cathinone-induced efflux. Neurochem Int. 2019;123:7–12.
pubmed: 30248432
doi: 10.1016/j.neuint.2018.09.008
Williams JM, Owens WA, Turner GH, Saunders C, Dipace C, Blakely RD, et al. Hypoinsulinemia regulates amphetamine-induced reverse transport of dopamine. PLoS Biol. 2007;5:e274.
pubmed: 17941718
pmcid: 2020502
doi: 10.1371/journal.pbio.0050274
Daws LC, Owens WA, Toney GM Using high-speed chronoamperometry to measure biogenic amine release and uptake in vivo. In: Bönisch H, Sitte HH (eds). Neurotransmitter transporters, vol. 118. Springer New York: New York, NY, 2016, pp 53-81.
Daws LC, Toney GM High-speed chronoamperometry to study kinetics and mechanisms for serotonin clearance in vivo. In: Michael AC, Borland LM (eds). Electrochemical methods for neuroscience. CRC Press/Taylor & Francis: Boca Raton (FL), 2007.
Holleran KM, Rose JH, Fordahl SC, Benton KC, Rohr KE, Gasser PJ, et al. Organic cation transporter 3 and the dopamine transporter differentially regulate catecholamine uptake in the basolateral amygdala and nucleus accumbens. Eur J Neurosci. 2020;52:4546–62.
pubmed: 32725894
doi: 10.1111/ejn.14927
Robinson DL, Lara JA, Brunner LJ, Gonzales RA. Quantification of ethanol concentrations in the extracellular fluid of the rat brain: In vivo calibration of microdialysis probes. J Neurochem. 2000;75:1685–93.
pubmed: 10987851
doi: 10.1046/j.1471-4159.2000.0751685.x
Yim HJ, Schallert T, Randall PK, Gonzales RA. Comparison of local and systemic ethanol effects on extracellular dopamine concentration in rat nucleus accumbens by microdialysis. Alcohol Clin Exp Res. 1998;22:367–74.
pubmed: 9581642
doi: 10.1111/j.1530-0277.1998.tb03662.x
Fuh MR, Tai YL, Pan WH. Determination of free-form of cocaine in rat brain by liquid chromatography-electrospray mass spectrometry with in vivo microdialysis. J Chromatogr B Biomed Sci Appl. 2001;752:107–14.
pubmed: 11254184
doi: 10.1016/S0378-4347(00)00531-4
Nicolaysen LC, Pan HT, Justice JB Jr. Extracellular cocaine and dopamine concentrations are linearly related in rat striatum. Brain Res. 1988;456:317–23.
pubmed: 3208083
doi: 10.1016/0006-8993(88)90234-X
Daws LC, Callaghan PD, Moron JA, Kahlig KM, Shippenberg TS, Javitch JA, et al. Cocaine increases dopamine uptake and cell surface expression of dopamine transporters. Biochem Biophys Res Commun. 2002;290:1545–50.
pubmed: 11820798
doi: 10.1006/bbrc.2002.6384
Clauss NJ, Koek W, Daws LC. Role of organic cation transporter 3 and plasma membrane monoamine transporter in the rewarding properties and locomotor sensitizing effects of amphetamine in male andfemale mice. Int J Mol Sci. 2021;22:13420.
pubmed: 34948221
pmcid: 8708598
doi: 10.3390/ijms222413420
Koek W. Morphine-induced conditioned place preference and effects of morphine pre-exposure in adolescent and adult male c57bl/6j mice. Psychopharmacology. 2016;233:2015–24.
pubmed: 25066361
doi: 10.1007/s00213-014-3695-y
Grundemann D, Schechinger B, Rappold GA, Schomig E. Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci. 1998;1:349–51.
pubmed: 10196521
doi: 10.1038/1557
Thierauf-Emberger A, Echle J, Dacko M, Lange T. Comparison of ethanol concentrations in the human brain determined by magnetic resonance spectroscopy and serum ethanol concentrations. Int J Leg Med. 2020;134:1713–8.
doi: 10.1007/s00414-020-02325-w
Sulzer D. How addictive drugs disrupt presynaptic dopamine neurotransmission. Neuron. 2011;69:628–49.
pubmed: 21338876
pmcid: 3065181
doi: 10.1016/j.neuron.2011.02.010
Eisenhofer G. The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharm Ther. 2001;91:35–62.
doi: 10.1016/S0163-7258(01)00144-9
Solis E Jr, Zdravkovic I, Tomlinson ID, Noskov SY, Rosenthal SJ, De Felice LJ. 4-(4-(dimethylamino)phenyl)-1-methylpyridinium (app+) is a fluorescent substrate for the human serotonin transporter. J Biol Chem. 2012;287:8852–63.
pubmed: 22291010
pmcid: 3308769
doi: 10.1074/jbc.M111.267757
Karpowicz RJ Jr, Dunn M, Sulzer D, Sames D. App+, a fluorescent analogue of the neurotoxin mpp+, is a marker of catecholamine neurons in brain tissue, but not a fluorescent false neurotransmitter. ACS Chem Neurosci. 2013;4:858–69.
pubmed: 23647019
pmcid: 3656749
doi: 10.1021/cn400038u
Kristensen AS, Andersen J, Jorgensen TN, Sorensen L, Eriksen J, Loland CJ, et al. Slc6 neurotransmitter transporters: Structure, function, and regulation. Pharm Rev. 2011;63:585–640.
pubmed: 21752877
doi: 10.1124/pr.108.000869
Bardo MT, Bevins RA. Conditioned place preference: What does it add to our preclinical understanding of drug reward? Psychopharmacology. 2000;153:31–43.
pubmed: 11255927
doi: 10.1007/s002130000569
Cunningham CL, Niehus DR, Malott DH, Prather LK. Genetic differences in the rewarding and activating effects of morphine and ethanol. Psychopharmacology. 1992;107:385–93.
pubmed: 1352057
doi: 10.1007/BF02245166
Beatty WW, Holzer GA. Sex differences in stereotyped behavior in the rat. Pharm Biochem Behav. 1978;9:777–83.
doi: 10.1016/0091-3057(78)90356-8
Brass CA, Glick SD. Sex differences in drug-induced rotation in two strains of rats. Brain Res. 1981;223:229–34.
pubmed: 7284807
doi: 10.1016/0006-8993(81)90830-1
Siuciak JA, McCarthy SA, Chapin DS, Reed TM, Vorhees CV, Repaske DR. Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1b (pde1b) enzyme. Neuropharmacology. 2007;53:113–24.
pubmed: 17559891
doi: 10.1016/j.neuropharm.2007.04.009
van den Buuse M, Halley P, Hill R, Labots M, Martin S. Altered n-methyl-d-aspartate receptor function in reelin heterozygous mice: Male-female differences and comparison with dopaminergic activity. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37:237–46.
pubmed: 22361156
doi: 10.1016/j.pnpbp.2012.02.005
Robinson TE, Berridge KC. Addiction. Annu Rev Psychol. 2003;54:25–53.
pubmed: 12185211
doi: 10.1146/annurev.psych.54.101601.145237
Becker JB, Chartoff E. Sex differences in neural mechanisms mediating reward and addiction. Neuropsychopharmacology. 2019;44:166–83.
pubmed: 29946108
doi: 10.1038/s41386-018-0125-6
Althobaiti YS, Sari Y. Alcohol interactions with psychostimulants: An overview of animal and human studies. J Addict Res Ther. 2016;7:281.
pubmed: 27478679
pmcid: 4966675
doi: 10.4172/2155-6105.1000281
Busse GD, Lawrence ET, Riley AL. The modulation of cocaine-induced conditioned place preferences by alcohol: Effects of cocaine dose. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:149–55.
pubmed: 14687869
doi: 10.1016/j.pnpbp.2003.09.031
Lewis MJ, June HL. Synergistic effects of ethanol and cocaine on brain stimulation reward. J Exp Anal Behav. 1994;61:223–9.
pubmed: 8169571
pmcid: 1334410
doi: 10.1901/jeab.1994.61-223
Busse GD, Lawrence ET, Riley AL. The effects of alcohol preexposure on cocaine, alcohol and cocaine/alcohol place conditioning. Pharm Biochem Behav. 2005;81:459–65.
doi: 10.1016/j.pbb.2005.04.003
Vanderschuren LJ, Pierce RC. Sensitization processes in drug addiction. Curr Top Behav Neurosci. 2010;3:179–95.
pubmed: 21161753
doi: 10.1007/7854_2009_21
Parker CC, Lusk R, Saba LM. Alcohol sensitivity as an endophenotype of alcohol use disorder: Exploring its translational utility between rodents and humans. Brain Sci. 2020;10:725.
pubmed: 33066036
pmcid: 7600833
doi: 10.3390/brainsci10100725
Boyce-Rustay JM, Wiedholz LM, Millstein RA, Carroll J, Murphy DL, Daws LC, et al. Ethanol-related behaviors in serotonin transporter knockout mice. Alcohol Clin Exp Res. 2006;30:1957–65.
pubmed: 17117959
doi: 10.1111/j.1530-0277.2006.00241.x
Bonisch H. Substrates and inhibitors of organic cation transporters (OCTS) and plasma membrane monoamine transporter (PMAT) and therapeutic implications. Handb Exp Pharm. 2021;266:119–67.
doi: 10.1007/164_2021_516
Brodie MS, Pesold C, Appel SB. Ethanol directly excites dopaminergic ventral tegmental area reward neurons. Alcohol Clin Exp Res. 1999;23:1848–52.
pubmed: 10591603
doi: 10.1111/j.1530-0277.1999.tb04082.x
Gessa GL, Muntoni F, Collu M, Vargiu L, Mereu G. Low doses of ethanol activate dopaminergic neurons in the ventral tegmental area. Brain Res. 1985;348:201–3.
pubmed: 2998561
doi: 10.1016/0006-8993(85)90381-6
Mereu G, Fadda F, Gessa GL. Ethanol stimulates the firing rate of nigral dopaminergic neurons in unanesthetized rats. Brain Res. 1984;292:63–69.
pubmed: 6697212
doi: 10.1016/0006-8993(84)90890-4
Stobbs SH, Ohran AJ, Lassen MB, Allison DW, Brown JE, Steffensen SC. Ethanol suppression of ventral tegmental area GABA neuron electrical transmission involves n-methyl-d-aspartate receptors. J Pharm Exp Ther. 2004;311:282–9.
doi: 10.1124/jpet.104.071860
Saeed Dar M, Wooles WR. The effect of acute ethanol on dopamine metabolism and other neurotransmitters in the hypothalamus and the corpus striatum of mice. J Neural Transm. 1984;60:283-94.
Mayfield RD, Maiya R, Keller D, Zahniser NR. Ethanol potentiates the function of the human dopamine transporter expressed in xenopus oocytes. J Neurochem. 2001;79:1070–9.
pubmed: 11739621
doi: 10.1046/j.1471-4159.2001.00656.x
Ho M, Segre M. Individual and combined effects of ethanol and cocaine on the human dopamine transporter in neuronal cell lines. Neurosci Lett. 2001;299:229–33.
pubmed: 11165777
doi: 10.1016/S0304-3940(01)01526-9
Niello M, Gradisch R, Loland CJ, Stockner T, Sitte HH. Allosteric modulation of neurotransmitter transporters as a therapeutic strategy. Trends Pharm Sci. 2020;41:446–63.
pubmed: 32471654
doi: 10.1016/j.tips.2020.04.006
Maiya R, Buck KJ, Harris RA, Mayfield RD. Ethanol-sensitive sites on the human dopamine transporter. J Biol Chem. 2002;277:30724–9.
pubmed: 12070173
doi: 10.1074/jbc.M204914200
Alexi T, Azmitia EC. Ethanol stimulates [3h]5-ht high-affinity uptake by rat forebrain synaptosomes: Role of 5-ht receptors and voltage channel blockers. Brain Res. 1991;544:243–7.
pubmed: 1645610
doi: 10.1016/0006-8993(91)90060-9
Bowman MA, Mitchell NC, Owens WA, Horton RE, Koek W, Daws LC, et al. Effect of concurrent organic cation transporter blockade on norepinephrine clearance inhibiting- and antidepressant-like actions of desipramine and venlafaxine. Eur J Pharm. 2020;883:173285.
doi: 10.1016/j.ejphar.2020.173285
Becker JB, Hu M. Sex differences in drug abuse. Front Neuroendocrinol. 2008;29:36–47.
pubmed: 17904621
doi: 10.1016/j.yfrne.2007.07.003
Anker JJ, Carroll ME. Females are more vulnerable to drug abuse than males: Evidence from preclinical studies and the role of ovarian hormones. Curr Top Behav Neurosci. 2011;8:73–96.
pubmed: 21769724
doi: 10.1007/7854_2010_93
Ciudad-Roberts A, Camarasa J, Ciudad CJ, Pubill D, Escubedo E. Alcohol enhances the psychostimulant and conditioning effects of mephedrone in adolescent mice; postulation of unique roles of d3 receptors and bdnf in place preference acquisition. Br J Pharm. 2015;172:4970–84.
doi: 10.1111/bph.13266
Lopez-Arnau R, Buenrostro-Jauregui M, Camarasa J, Pubill D, Escubedo E. Effect of the combination of mephedrone plus ethanol on serotonin and dopamine release in the nucleus accumbens and medial prefrontal cortex of awake rats. Naunyn Schmiedebergs Arch Pharm. 2018;391:247–54.
doi: 10.1007/s00210-018-1464-x
Duan H, Wang J. Impaired monoamine and organic cation uptake in choroid plexus in mice with targeted disruption of the plasma membrane monoamine transporter (slc29a4) gene. J Biol Chem. 2013;288:3535–44.
pubmed: 23255610
doi: 10.1074/jbc.M112.436972
Perez-Reyes M, Jeffcoat AR. Ethanol/cocaine interaction: Cocaine and cocaethylene plasma concentrations and their relationship to subjective and cardiovascular effects. Life Sci. 1992;51:553–63.
pubmed: 1640806
doi: 10.1016/0024-3205(92)90224-D
Melis M, Diana M, Enrico P, Marinelli M, Brodie MS. Ethanol and acetaldehyde action on central dopamine systems: Mechanisms, modulation, and relationship to stress. Alcohol. 2009;43:531–9.
pubmed: 19913196
pmcid: 2778604
doi: 10.1016/j.alcohol.2009.05.004
Dworkin SI, Mirkis S, Smith JE. Response-dependent versus response-independent presentation of cocaine: Differences in the lethal effects of the drug. Psychopharmacology. 1995;117:262–6.
pubmed: 7770601
doi: 10.1007/BF02246100
Moolten M, Kornetsky C. Oral self-administration of ethanol and not experimenter-administered ethanol facilitates rewarding electrical brain stimulation. Alcohol. 1990;7:221–5.
pubmed: 2184835
doi: 10.1016/0741-8329(90)90008-Z
Porrino LJ, Esposito RU, Seeger TF, Crane AM, Pert A, Sokoloff L. Metabolic mapping of the brain during rewarding self-stimulation. Science. 1984;224:306–9.
pubmed: 6710145
doi: 10.1126/science.6710145
Khanppnavar B, Maier J, Herborg F, Gradisch R, Lazzarin E, Luethi D, et al. Structural basis of organic cation transporter-3 inhibition. Nat Commun. 2022;13:6714.
pubmed: 36344565
pmcid: 9640557
doi: 10.1038/s41467-022-34284-8
Lin L, Yee SW, Kim RB, Giacomini KM. Slc transporters as therapeutic targets: Emerging opportunities. Nat Rev Drug Discov. 2015;14:543–60.
pubmed: 26111766
pmcid: 4698371
doi: 10.1038/nrd4626